Search in site
BlueWind Medical is an innovative medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has grown to an established company with diverse, creative and committed employees.
BlueWind Medical has successfully completed several clinical studies with excellent results and is focused on bringing this breakthrough RENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market
We will provide safe and effective peripheral neuromodulation solutions for patients suffering from neurological disorders
We are helping patients around the world, initially focusing on tibial nerve modulation by treating pelvic floor disorders, including over-active bladder
Mr. Roy Katz brings to BlueWind Medical more than two decades of global and cross-cultural leadership and business experience in the medical device industry, in both startups and large corporations. Prior to joining BlueWind Medical, Roy served as Vice President for Business Development for Rainbow Medical, a medical device investment firm and technology incubator. Previously, Roy served as marketing director for Rhythmia Medical, a venture-backed medical device startup that was acquired by Boston Scientific in 2012. Prior to joining Rhythmia, Roy held several marketing positions at Medtronic HQ in Minneapolis, MN.
Roy holds an MBA from the Kellogg School of Management, a master’s degree in engineering management from the McCormick School of Engineering at Northwestern University in Evanston, Illinois, and a B.Sc. in engineering from the Technion in Haifa.
Mr. Dan Lemaitre joined BlueWind Medical as Executive Chairman in September 2018 and serves as CEO since January 2020.
Dan is also Chairman of Endologix (NYSE: ELGX) an Irvine California company that is focused on aortic disorders with ~$150 million in annual sales and 650 employees.
Dan also serves on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$700 million per annum.
Previously, Dan was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. Prior to joining CoreValve, Dan was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development.
Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.
Mr. Guri Oron has co-founded Bluewind and been with the company since its inception. He has over 15 years of experience in executive R&D roles, primarily with startups in the medical device field with specific expertise in Neurostimulation technologies. Throughout his career Guri managed complex R&D projects from their ideation through design, engineering, regulatory and clinical development. Prior to working with BlueWind Medical, Guri founded and was the CEO of Cybotech, a multinational financial software company. Early on in his career Guri led the R&D at BrainsGate and served for almost 10 years in the IDF Intelligence Technological Unit. Guri holds a B.Sc. in Electrical Engineering from Tel Aviv University. He is the lead inventor or co-inventor of numerous patent and patent pending applications
Dr. Roger Dmochowski is a world-renowned leader in the fields of urology, OAB and incontinence, a recipient of the Zimskind Award and Lifetime Achievement Awards from the Urodynamics Society for his accomplishments in the clinical treatment for incontinence, a Fellow of the American College of Surgeons, a member of the American Urological Association and International Continence Society, and a trustee of the American Board of Urology. An accomplished scholar, Dr. Dmochowski has published over 320 articles, 100 book chapters and 460 abstracts, given over 260 presentations at various national and international meetings, led and participated in dozens of OAB and incontinence studies, is the Editor-in-Chief of NeuroUrology and Urodynamics, and serves on the editorial board for several scientific journals.
Mrs. Ofri Vaisman is bringing to Bluewind Medical her extensive experience in leading global cross-functional teams in the realization of new medical technologies from the initial concept, through product development, regulatory clearance and commercialization. Prior to joining the Company Ofri was the Director of the Medical Program at Aspect Imaging where she was responsible for the business strategy and product development of a novel Neonatal MRI system. Prior to that, Ofri was the Director of Program Management at Galil Medical (acquired by BTG) directing the development and commercialization of the minimally invasive disposable products. Ofri has also led product and strategic projects at J&J’s Biosense Webster based in California and worked as a consultant to Medical Device start-ups at Ernst & Young. Ofri holds a B.A. (Magna Cum Laude) in Psychology and Science studies from the Hebrew University and an MBA (Summa Cum Laude) from Tel Aviv University.
Ms. Roni Diaz brings her 24 years of experience in medical device clinical trial management to the table at Bluewind Medical. Prior to joining the company, Roni was Director of Clinical Research at Insightec in Dallas, Texas, where she was responsible for the planning, oversight and organization of US and OUS feasibility, pre-approval, and post-approval studies for a Class III medical device. Before Insightec, Roni was the Global Director of Clinical Affairs for 13 years at Abbott Neuromodulation (formerly St. Jude Medical) in Plano, Texas. She was responsible for oversight of the chronic pain portfolio of studies, including protocol development, study execution, publication planning, and regulatory body submissions. Roni has a B.Sc. in Health Sciences from San Jose State University.
Dr. Karin Aharonson-Raz is a biomedical scientist, trained as a veterinarian doctor and holds a PhD in Epidemiology, with a multidisciplinary research background in neuroscience, immunology and epidemiology. She has been in BlueWind Medical from early stages and was involved as the company transitioned from pre-clinical to clinical phases leading the science research, pre-clinical, clinical and regulatory fields.
Mr. Moshe Ben-Chorin has more than 20 years of experience in the high-tech industry. Prior to joining Bluewind Medical, he served as Vice President of the High-Tech Programs at Ramot, the business engagement center of Tel Aviv University. Before that, he served as VP R&D and headed the system engineering group at Aspect Imaging, where he was involved in the development of medical and pre-clinical MRI systems. Prior to that, Moshe held R&D positions at various companies, including being a co-founder and chief scientist of Genoa Color Technologies, where he guided the development of multi-primary display technology from idea to maturation. Moshe holds a Ph.D. in Physics from the Hebrew University of Jerusalem, and spent several years following graduation in academic research. He is an author of about 60 scientific publications and a co-inventor of more than 20 patent families.
Dr. Bar Eytan holds a Doctor's degree in veterinary medicine and has vast clinical experience in veterinary medicine and surgery. She also has over 10 years of experience in medical device research and development. Dr. Eytan has been with BlueWind Medical from the very early stages of the company and accompanied the BlueWind products and procedures from concept to clinical trials. Throughout her career in the medical device industry Dr. Eytan has served in a variety of roles involving both medical research as well as technical R&D work, bringing a multidisciplinary approach to her current role. Prior to working at BlueWind Medical Dr. Eytan worked in equine practice and in DenX, a medical device company in the field of dentistry.
Dr. Heesakkers studied Medicine at the Radboud University of Nijmegen. He started his training in Urology in 1993 at the University Hospital Maastricht. In 1997 he successfully defended his thesis titled: ‘Dynamic Urinary Graciloplasty’ at the University of Maastricht. Since 2000 he is a full-time staff urologist at the Department of Urology of the Radboud UMC and consultant at the Rehabilitation Clinic St Maarten in Nijmegen, the Netherlands. He is heading the Unit of Functional Urology and Neurourology. The Unit is officially recognized as national reference center for functional urological disorders and is part of the European Reference Network, a body of the EU. He is the founder and director of the Nijmegen University Pelvic Care Center Isabella. He chairs the Society of Functional and Reconstructive Urology, a body of the Dutch Association of Urology. Dr. Heesakkers is an active member of the EAU, ICS, SUFU and the AUA. He is a faculty member of the European School of Urology, the Scientific Office of the EAU and the Chairman of the European Section of Female and Functional Urology. Since 2008 he is a principal investigator for the Nijmegen Centre for Molecular Life Sciences. He is an associate editor of Neurourology and Urodynamics and reviewer of several major Urologic Scientific journals. He received about €2.5 million for research grants. He is the author of more than 100 peer-reviewed papers, 5 books and more than 10 book-chapters and books on urological topics.
Dr. Alex Digesu is a Consultant Obstetrician, Gynaecologist & Urogynaecology Subspecialist at St. Mary’s Hospital, London and Honorary Senior Lecturer at the Imperial College, London. Dr. Digesu completed his specialist training in Obstetrics & Gynaecology and Reproductive Medicine in Italy at the University of Bari in 2002. In 2005 he achieved his PhD in Oncological, Gynaecological and Geriatric Surgery from the same university. His clinical and academic experience also includes a five years fellowship in Urogynaecology in London at King’s College Hospital and St. Mary’s Hospital and two years subspecialty training in Urogynaecology & reconstructive pelvic floor surgery at Imperial College of London. Since 2008 Dr Digesu has also worked as Honorary Senior lecturer in Neurourology, at Beata Vergine Hospital in Mendrisio (Switzerland) where sees and treats lower urinary tract disorders (ie incontinence, voiding problems, urinary retention etc) in patients affected by multiple sclerosis and other neurological diseases. Since 2010 Dr Digesu has been accredited by the Royal College of Obstericians and Gynaecologists as a Specialist in Urogynaecology (specialised in treating patients with bladder & bowel problems such as incontinence and uterovaginal prolapse during pregnancy and after childbirth).
Philip E.V. Van Kerrebroeck is Professor of Urology at the University of Maastricht, and works as a urologist at the Maastricht University Medical Centre, the Netherlands. After obtaining his Medical Degree from the University of Louvain, Belgium, he trained in General Surgery and Urology in Belgium, The Netherlands and the USA. He received his Master’s Degree in Medical Sciences from the University of Antwerp, Belgium, and his PhD in Medicine from the Radboud University of Nijmegen, The Netherlands. Professor Van Kerrebroeck has a long-standing clinical interest in different forms of lower urinary tract problems, both in women and men, including neurogenic bladder dysfunction. His research interests include electrical stimulation of the urinary tract, and the development of new therapies in Neuro-Urology and Functional Urology. Professor Van Kerrebroeck was for 8 years Chairman of the Standardisation Committee of the International Continence Society and was first author of the Standardisation report on Nocturia. He is Fellow of the European Board of Urology. He was involved in the New England Research Institutes Interdisciplinary Conferences on Nocturia and is past Chairman of the ICI-RS Nocturia Think Tank. Professor Van Kerrebroeck is a member of 25 scientific societies; he serves on the editorial board of six journals, and has authored over 265 peer-reviewed articles, book chapters and books. He currently serves as a member of the History Office of the EAU.
Dr. Elneil is a Consultant Urogynaecologist and Uro-neurologist at University College Hospital and the National Hospital for Neurology and Neurosurgery in London. At the National Hospital for Neurology and Neurosurgery, she runs the neuromodulation program for bladder and pelvic floor dysfunction, which is used in patients in whom most other treatment modalities have failed.
Over the last decade, Dr. Elneil has developed the field of neuro-urogynaecology. Her research program is focused on the neuropathology of bladder/bowel/pelvic floor dysfunction and the role of innovative therapy in restoring function to these sites. She is also teaching and training junior and senior colleagues in the two specialties in the UK and further afield.
Miss Elneil is the Training Program Director for Urogynaecology at University College London Hospitals, Clinical lead for Uro-neurology training for some UK trainees undertaking the RCOG-accredited subspecialty training program. She is Chair of the RCOG Global Health Program Development Committee, Chair of the IUGA working group on Neuro-urogynaecology and Chronic Pelvic Pain, President of the RSM Pain Council, Author/Editor of the FIGO and partners Fistula training manual and numerous other positions, Member of the ICS Standardization Committee and Member of the EAU Chronic Pelvic Pain Committee.
Dr. Van Buyten received his doctorate in Medical Science, Surgery and Obstetrics from the Free University of Brussels, Belgium in 1980. From 1980 to 1984, he continued his training in anesthesia and intensive care at the University Hospital in Antwerp, Belgium; in pain therapy at the University Hospital in Gent; in neuroanesthesia at CHU Montpellier, France; and in obstetric anesthesia at the CHU Pitie-Salpetriere Paris, France. In 1997, he graduated with a specialized degree in intensive care medicine.
Dr. Van Buyten is currently the Chairman of the Multidisciplinary Pain Center AZ Nikolaas Sint-Niklaas in Belgium. Dr. Van Buyten is a respected and highly sought-after international lecturer on pain management, and is an active researcher in the field. He has been widely published in many scientific journals, is a member in many prestigious scientific societies—including the Belgian Association for Anesthesia-Reanimation, the European Society Regional Anesthesia, the Flemish Pain Society for Anesthesiologists, and the International Neuromodulation Society.
Director of the Pain Research Unit at the Institute of Pain Medicine, Rambam Health Care Campus and a Professor of Neurology and Pain Medicine at the Faculty of Medicine in the Technion - Institute of Technology, Israel.
Mr. Dan Lemaitre joined BlueWind Medical as Executive Chairman in September 2018 and serves as CEO since January 2020. Dan is also Chairman of Endologix (NYSE: ELGX) an Irvine California company that is focused on aortic disorders with ~$150 million in annual sales and 650 employees. Dan also serves on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$700 million per annum. Previously, Dan was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. Prior to joining CoreValve, Dan was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development. Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.
Mr. Neugarten has over 35 years of senior managerial experience, and over 15 years of experience in the medical industry. He brings to BlueWind Medical significant experience in medical devices venture capital investments, commercialization, and asset realization. Mr. Neugarten serves as Executive Chairman of Rainbow Medical, BlueWind’s founding and largest investor. Previously, he was a partner at DOR Ventures, a VC fund focusing on imaging technologies as part of the Viola Partners Group. During his period at DOR Ventures he led various investments including medical imaging ventures. Since 2006, he led the healthcare investments of Viola Partners, and currently serves on the boards of Angioslide, NanoPass, and PainReform. Prior to joining the Viola Partners Group, he worked for Scitex (NASDAQ:SCIX) in various management positions in Europe, Japan, and Israel. He received his BSc in Electronics from the Technion, Haifa Israel, and an MBA from Boston University.
Mr. Cohen brings to BlueWind Medical significant experience in finance, taxes, accounting, and M&As. Mr. Cohen is CFO for Rainbow Medical, BlueWind’s founding and largest investor. Prior to joining Rainbow Medical, Mr. Cohen served as group corporate controller for several companies among them SuperDerivatives Ltd., Verisity Ltd. (NASDAQ: VRST. Mr. Cohen spent four years in public accounting at Kesselman & Kesselman (PwC Israel) in Tel Aviv and PricewaterhouseCoopers in San Jose, California, where he was responsible for hi-tech clients. Mr. Cohen is certified as a CPA in Israel, and holds a BA in economics and accounting and an executive MBA, both from Bar-Ilan University.